文献速递血栓与止血MDS 与骨髓增殖性肿瘤

从布加综合征到获得性血管性血友病综合征:骨髓增殖性肿瘤中的血栓与出血并发症

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
PubMed 文献 · Blood · 2019-01-01

该综述聚焦原发性血小板增多症、真性红细胞增多症和骨髓纤维化患者中常见的血栓与出血并发症,指出降低血栓和/或出血风险是主要治疗目标。文章回顾了传统风险分层因素(高龄、血栓史)以外的多种促血栓因素(性别、突变谱、炎症应激、异常细胞黏附),并讨论了抗血小板、抗凝、降细胞治疗及特殊情境(非常见部位血栓、出血、围手术期、妊娠)的管理策略,指出近期研究有望推动更精准的风险分类和个体化治疗。

要点

  • 骨髓增殖性肿瘤患者血栓和出血风险高,降低风险是主要治疗目标。
  • 风险分层除高龄和血栓史外,还需考虑性别、突变谱、炎症应激和异常细胞黏附。
  • 管理包括心血管风险控制、抗血小板、抗凝和降细胞治疗,特殊情境处理具有挑战性。

核心结论

  • 骨髓增殖性肿瘤患者血栓和出血并发症常见,降低其风险是主要治疗目标,近期研究有望推动更精准的风险分类和个体化治疗。

研究设计与样本

  • 本文为综述,回顾了骨髓增殖性肿瘤血栓和出血的风险因素及治疗策略,包括特殊情境的管理。

主要发现

  • 除传统因素如高龄和血栓史外,性别、突变谱、炎症应激和异常细胞黏附等多因素共同促进血栓倾向。
  • 管理包括心血管风险降低和抗血小板治疗,取决于骨髓增殖性肿瘤亚型和突变状态;静脉血栓以抗凝为基础治疗,但实践模式仍存在异质性。
  • 降细胞治疗适用于较高危患者,但疗效可能取决于受累血管床;非常见部位血栓、出血、围手术期和妊娠等特殊情境管理尤为挑战。

临床怎么用

  • 应根据骨髓增殖性肿瘤亚型和突变状态决定抗血小板治疗,静脉血栓患者以抗凝为基础治疗。
  • 较高危患者应接受降细胞治疗,但需考虑受累血管床对疗效的影响。
  • 特殊情境如非常见部位血栓、出血、围手术期和妊娠需个体化处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a major therapeutic goal. Historically, patients have been risk stratified on the basis of traditional factors, such as advanced age and thrombosis history. However, multiple factors contribute to the thrombotic tendency, including gender, mutational profile, inflammatory stress, and abnormal cell adhesion. Management includes cardiovascular risk reduction and use of antiplatelet therapy, depending on myeloproliferative neoplasm subtype and mutational status. Anticoagulation is a mainstay of therapy for those with venous thrombosis, but practice patterns remain heterogeneous. Cytoreduction is indicated for higher-risk patients, but efficacy may depend on the involved vascular bed. Management of special situations, such as unusual site thrombosis, bleeding, the perioperative period, and pregnancy, are especially challenging. In this article, risk factors and treatment strategies for myeloproliferative neoplasm thrombosis and bleeding, including special situations, are reviewed. Insights gained from recent studies may lead to the development of a more precise risk classification and tailored therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood. 2019. PMID: 31778549. doi:10.1182/blood.2019001318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。